Physician profile
Christopher A Thomas
NPI 1285012864
$7,751.30
in general payments reported to CMS, 2019-2025
19 companies · $1,544 in 2025
The $1,544 reported for 2025 was more than what 84% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $462 · 2023: $3,819 · 2024: $1,926 · 2025: $1,544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,315 · Consulting Fee: $2,100 · Travel and Lodging: $810 · Education: $63.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,314.93 |
| Consulting Fee | $2,100.00 |
| Travel and Lodging | $810.06 |
| Education | $63.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $3,870.90 | 2022-2025 | Opsumit, Uptravi, Opsynvi |
| United Therapeutics Corporation | $1,441.82 | 2022-2025 | Tyvaso, Remodulin, Remodulin |
| Ani Pharmaceuticals, INC. | $539.28 | 2024-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $408.08 | 2023-2025 | Ofev, Jascayd |
| Bayer Healthcare Pharmaceuticals INC. | $311.01 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $225.29 | 2022-2025 | Livtencity |
| Merck Sharp & Dohme LLC | $197.58 | 2024-2025 | Winrevair |
| Abbvie INC. | $150.72 | 2023-2025 | Avycaz, Teflaro |
| Insmed, INC. | $121.14 | 2025 | Arikayce, Brinsupri |
| Vifor Pharma, INC. | $113.44 | 2024 | Zemaira |
| Mylan Specialty L.P. | $111.51 | 2023-2024 | Tobi Podhaler |
| Paratek Pharmaceuticals, INC. | $57.72 | 2024 | Nuzyra |
| Melinta Therapeutics, LLC | $54.50 | 2024 | Rezzayo, Vabomere |
| Mallinckrodt Hospital Products INC. | $42.61 | 2023 | Acthar |
| Invivyd INC | $31.35 | 2025 | Pemgarda |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Health Care Systems INC. | $20.93 | 2025 | Opsumit, Uptravi |
| Baxter Healthcare | $19.24 | 2025 | Hillrom - Monarch Airway Clearance System |
| La Jolla Pharmaceutical Company | $18.19 | 2025 | Giapreza |
| Eurofins Viracor, LLC | $15.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.